Want to see ENDV full AI Analyst Report?

Endonovo Therapeutics (ENDV) Price & Analysis

24 Followers

ENDV Stock Chart & Stats

<$0.01

>-$0.01(-30.00%)

At close: Jan 08 4:00 PM EST

<$0.01

>-$0.01(-30.00%)

Day’s Range― - ―

52-Week Range― - ―

Previous CloseN/A

Volume29.52M

Average Volume (3M)N/A

Market Cap

$180.76K

Enterprise Value$6.93M

Total Cash (Recent Filing)$3.00

Total Debt (Recent Filing)$6.87M

Price to Earnings (P/E)―

Beta231.29

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,807,556,300

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)>-0.01

Price to Sales (P/S)0.00

P/FCF Ratio-2.55

Enterprise Value/Market Cap38.33

Enterprise Value/Revenue689.80

Enterprise Value/Gross Profit-11.26

Enterprise Value/Ebitda-7.36

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Innovative Product OfferingEndonovo's focus on non-invasive, bioelectronic therapies positions it well in the growing field of regenerative medicine, offering a unique solution for pain management and recovery.

Revenue Model DiversityA diverse revenue model including sales, leases, and partnerships enhances revenue stability and potential growth through multiple streams.

Cash Flow ImprovementImprovement in free cash flow indicates better cash management, which is crucial for sustaining operations and funding future growth initiatives.

Bears Say

Financial InstabilityNegative equity and high liabilities indicate financial distress, posing risks to long-term viability and limiting strategic options.

Revenue DeclineInconsistent revenue trends undermine financial stability and growth prospects, challenging the company's ability to sustain operations.

Profitability ChallengesNegative margins highlight operational inefficiencies and cost management issues, impacting the company's ability to achieve profitability.

ENDV FAQ

What was Endonovo Therapeutics’s price range in the past 12 months?

Currently, no data Available

What is Endonovo Therapeutics’s market cap?

Endonovo Therapeutics’s market cap is $180.76K.

When is Endonovo Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Endonovo Therapeutics’s earnings last quarter?

Currently, no data Available

Is Endonovo Therapeutics overvalued?

According to Wall Street analysts Endonovo Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Endonovo Therapeutics pay dividends?

Endonovo Therapeutics does not currently pay dividends.

What is Endonovo Therapeutics’s EPS estimate?

Endonovo Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Endonovo Therapeutics have?

Endonovo Therapeutics has 1,807,556,300 shares outstanding.

What happened to Endonovo Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Endonovo Therapeutics?

Currently, no hedge funds are holding shares in ENDV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.